Plant Comparison
Goldenseal vs Perforate St John’s-wort
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Goldenseal and Perforate St John’s-wort: they share 5 indicated uses (arthritis / joint pain, infection (general), inflammation (general), …); 1 pharmacological action in common.
Evidence face-off — shared uses
| Condition | Goldenseal | Perforate St John’s-wort | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 5/10 | 1/10 | Stronger for Goldenseal |
| Infection (general) | 5/10 | 1/10 | Stronger for Goldenseal |
| Inflammation (general) | 5/10 | 1/10 | Stronger for Goldenseal |
| Skin irritation | 5/10 | 1/10 | Stronger for Goldenseal |
| Wounds | 5/10 | 1/10 | Stronger for Goldenseal |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Berberine is the main antimicrobial, hypoglycaemic and hypolipidaemic constituent. Notably, whole-leaf extracts are more potent against MRSA than isolated berberine (owing to efflux-pump-inhibitory flavonoids) and show quorum-quenching, anti-virulence activity.
Red pigments historically used to standardise extracts; contribute to antiviral activity and are the compounds responsible for photosensitivity risk.
Considered the principal compound behind the antidepressant activity and the main driver of the herb's potent CYP3A4/P-glycoprotein induction and drug-interaction profile.
Antioxidant flavonoids contributing to overall activity.
Pharmacological Actions
Anti-inflammatory and astringent for inflamed mucous membranes (sore-throat gargle, mouth)
Antimicrobial (berberine) - supports skin, mucosal and gastrointestinal infections and sore throat
Anti-inflammatory and astringent for inflamed mucous membranes (sore-throat gargle, mouth)
Traditional & Indicated Uses
inferred from anti-inflammatory action
Digestive / gastrointestinal support (traditional for dyspepsia and ulcers)
Antimicrobial (berberine) - supports skin, mucosal and gastrointestinal infections and sore throat; Topical for skin infections and irritation - whole-leaf extract is active in vitro against methicillin-resistant Staphylococcus aureus (MRSA)
inferred from anti-inflammatory action
inferred from anti-inflammatory action
Anti-inflammatory and astringent for inflamed mucous membranes (sore-throat gargle, mouth); Antimicrobial (berberine) - supports skin, mucosal and gastrointestinal infections and sore throat
inferred from anti-inflammatory action
inferred from antiviral action
inferred from anti-inflammatory action
inferred from sedative action
inferred from anti-inflammatory action
Safety, Cautions & Contraindications
Contraindicated in pregnancy and breastfeeding: berberine crosses the placenta and into milk and can cause or worsen newborn jaundice (risk of kernicterus); do not give to infants.
Berberine strongly inhibits drug-metabolising enzymes (especially CYP3A4 and CYP2D6), so it can raise the blood levels of many medicines - a significant herb-drug-interaction risk. In a screen of commercial herbal products, goldenseal was among the most potent CYP2D6 inhibitors and also inhibited CYP3A4. High doses have shown possible liver, nerve and photo-toxicity.
Significant drug interactions: strongly induces CYP3A4 and P-glycoprotein, reducing plasma levels of many drugs including oral contraceptives, antiretrovirals, cyclosporine, warfarin, and digoxin. May cause photosensitivity (fair-skinned individuals). Do not combine with SSRIs, SNRIs, or MAOIs (serotonin syndrome risk). Avoid in bipolar disorder.
Duke (2002) rates St. John's wort as ++ (raised from earlier editions) and notes antidepressant, antiviral, antibacterial, and wound-healing activities at experimental and clinical levels. Hypericin and hyperforin are identified as key active constituents. Clinical evidence (score 2) confirms antidepressant efficacy in mild-to-moderate depression, and WHO/Commission E provide approval for this indication. Dose: 300 mg standardized extract (0.3% hypericin, 3–5% hyperforin) three times daily. Duke emphasizes the critical drug interaction: St. John's wort is a potent CYP3A4 inducer and can significantly reduce blood levels of many medications including oral contraceptives, cyclosporine, antiretrovirals, and warfarin. Avoid combined use with SSRIs (serotonin syndrome risk) and pharmaceutical antidepressants (Duke, 2002).
External Ids
Botanical Description
Low, woodland perennial herb rising from a knotted, bright yellow rhizome with wiry yellow roots. Each stem bears two ragged, palmately lobed, maple-like leaves and a single small, inconspicuous greenish-white flower, followed by a raspberry-like cluster of red berries.[1]
Erect, branching perennial herb with paired, oval leaves dotted with tiny translucent oil glands that look like pinpricks when held to the light (giving the species name 'perforatum'). Bright yellow, five-petalled flowers with numerous stamens and black dots along the petal edges are borne in flat-topped clusters, and release a reddish pigment when crushed.[4]
Habitat
Grows in rich, shaded deciduous woodland with humus-rich soil; native to eastern North America, now scarce in the wild due to overharvesting and largely supplied by cultivation.[1]
Grows in grassland, roadsides, woodland clearings and waste ground on well-drained soils; native to Europe, Western Asia and North Africa and widely naturalised elsewhere, including North America and Australia.[4]
Harvesting
The rhizome and root are dug in autumn from plants at least three to four years old, when berberine content is highest, then cleaned and dried; because wild populations are depleted, cultivated or sustainably sourced material is strongly preferred, and careful identification against the toxic mayapple and bloodroot, which share its woodland habitat, is essential before any wild-harvesting.[1]
The flowering tops (flower and upper leaf) are cut in summer as the flowers open, around the traditional St John's Day period, and dried quickly in a warm, shaded, airy place to preserve the hypericin and hyperforin content.[4]
Traditional Uses
Goldenseal root has a Native American and, after adoption by Eclectic physicians, wider North American tradition as a bitter tonic and antimicrobial remedy for mucous-membrane infections, sore throat, digestive upset and topical skin infections, directly reflecting its high berberine content.[1]
St John's wort has a centuries-long European folk reputation as a wound-healing and nerve tonic herb, traditionally used for mild wounds, burns and nerve pain and to lift low mood; this traditional mood-supporting use is now one of the most extensively clinically studied applications of any herbal medicine, with standardised extracts shown comparable to conventional antidepressants for mild-to-moderate depression.[1, 4]
Preparations
Dried rhizome and root simmered in water as a traditional bitter antimicrobial tea, or used as a gargle for sore throat.
Tincture 1:10 in 60% ethanol of the dried rhizome and root, 2-4 ml three times daily per the WHO monograph Rhizoma Hydrastis. Educational reference only, not a prescription.
Extract standardised to berberine/hydrastine content, taken as capsules; whole-leaf extracts have shown stronger antimicrobial activity than isolated berberine in some studies.
Flowering-top extract standardised to hypericin and/or hyperforin content, taken as tablets or capsules; the best-studied clinical form for mood support.
Dosage
The WHO monograph on Rhizoma Hydrastis gives a daily dose of 0.5-1.0 g of the dried rhizome and root three times, or taken as a decoction; a 1:1 liquid extract in 60% ethanol at 0.3-1.0 mL three times; or a 1:10 tincture in 60% ethanol at 2-4 mL three times. For short-term use only, given goldenseal's potent CYP-enzyme inhibition and its contraindication in pregnancy. Educational reference only, not a prescription.
Clinical trials for mild-to-moderate depression commonly use around 300 mg of standardised extract three times daily (900 mg/day total); given extensive drug interactions, use should be discussed with a healthcare provider, especially alongside other medicines. Educational reference only, not a prescription.
References
Drug Class Interactions
Lookalikes Review
Dangerous Lookalikes
Not documented
Pairings
Not documented
St John's wort raises serotonin activity and can cause serotonin syndrome when combined with other serotonin-boosting agents; pairing it with another mood-active, serotonergic herb such as saffron may add to this risk.[30]
St John's wort is a strong enzyme inducer and increases serotonin activity; combining it with another antidepressant-type herb such as rhodiola may add to serotonergic effects and unpredictably change how each is handled by the body.[30]
St John's wort speeds up the breakdown of many substances and also raises serotonin activity; pairing it with a sedative herb such as valerian may add to drowsiness and can unpredictably change how each is handled by the body.[30, 31]
St John's wort is a strong enzyme inducer and kava is a liver-metabolised sedative; combining them may add to central-nervous-system effects and alter how kava is processed, so combined use warrants caution.[30, 31]
References & Sources
- Mandal, S.K., Maji, A.K., Mishra, S.K., Ishfaq, P.M., Devkota, H.P., Silva, A.S. and Das, N (2020) 'Goldenseal (Hydrastis canadensis L.) and its active constituents: A critical review of their efficacy and toxicological issues', Pharmacological Research. doi:10.1016/j.phrs.2020.105085 Randomized trial
https://doi.org/10.1016/j.phrs.2020.105085 - Corn, J., Tibbitts, D., Ito, H., Schafer, M. and Vasilevsky, N (2021) 'Effects of Hydrastis Canadensis, Commiphora Habessinica, Phytolacca Americana, and Echinacea Purpurea on Bacterial Growth', Alternative Therapies in Health and Medicine, 27(4), pp. 24-27. Preclinical
https://scholar.google.com/scholar?q=Effects%20of%20Hydrastis%20Canadensis%2C%20Commiphora%20Habessinica%2C%20Phytolacca%20Americana%2C%20and%20Echinacea%20Purpurea%20on%20Bacterial%20Growth - Ettefagh, K.A., Burns, J.T., Junio, H.A., Kaatz, G.W. and Cech, N.B (2010) 'Goldenseal (Hydrastis canadensis L.) extracts synergistically enhance the antibacterial activity of berberine via efflux pump inhibition', Planta Medica, 77(8), pp. 835-840. doi:10.1055/s-0030-1250606 Preclinical
https://doi.org/10.1055/s-0030-1250606 - Cech, N.B., Junio, H.A., Ackermann, L.W., Kavanaugh, J.S. and Horswill, A.R (2012) 'Quorum quenching and antimicrobial activity of goldenseal (Hydrastis canadensis) against methicillin-resistant Staphylococcus aureus (MRSA)', Planta Medica, 78(14), pp. 1556--1561. doi:10.1055/s-0032-1315042 Traditional / reference
https://doi.org/10.1055/s-0032-1315042 - Mahady, G.B., Pendland, S.L., Stoia, A. and Chadwick, L.R (2003) 'In vitro susceptibility of Helicobacter pylori to isoquinoline alkaloids from Sanguinaria canadensis and Hydrastis canadensis', Phytotherapy Research, 17(3), pp. 217-221. doi:10.1002/ptr.1108 Preclinical
https://doi.org/10.1002/ptr.1108 - Junio, H.A., Sy-Cordero, A.A., Ettefagh, K.A., Burns, J.T., Micko, K.T., Graf, T.N., Richter, S.J., Cannon, R.E., Oberlies, N.H. and Cech, N.B (2011) 'Synergy-directed fractionation of botanical medicines: a case study with goldenseal (Hydrastis canadensis)', Journal of Natural Products, 74(7), pp. 1621-1629. doi:10.1021/np200336g Preclinical
https://doi.org/10.1021/np200336g - Britton, E.R., Kellogg, J.J., Kvalheim, O.M. and Cech, N.B (2017) 'Biochemometrics to Identify Synergists and Additives from Botanical Medicines: A Case Study with Hydrastis canadensis (Goldenseal)', Journal of Natural Products, 81(3), pp. 484-493. doi:10.1021/acs.jnatprod.7b00654 Preclinical
https://doi.org/10.1021/acs.jnatprod.7b00654 - Leyte-Lugo, M., Britton, E.R., Foil, D.H., Brown, A.R., Todd, D.A., Rivera-Chavez, J., Oberlies, N.H. and Cech, N.B (2017) 'Secondary Metabolites from the Leaves of the Medicinal Plant Goldenseal (Hydrastis canadensis)', Phytochemistry Letters, 20, pp. 54-60. doi:10.1016/j.phytol.2017.03.012 Preclinical
https://doi.org/10.1016/j.phytol.2017.03.012 - Gurley, B.J., Swain, A., Hubbard, M.A., Hartsfield, F., Thaden, J., Williams, D.K., Gentry, W.B. and Tong, Y (2007) 'Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo', Clinical Pharmacology and Therapeutics, 83(1), pp. 61-69. doi:10.1038/sj.clpt.6100222 Randomized trial
https://doi.org/10.1038/sj.clpt.6100222 - Wallace, E.D., Oberlies, N.H., Cech, N.B. and Kellogg, J.J (2018) 'Detection of adulteration in Hydrastis canadensis (goldenseal) dietary supplements via untargeted mass spectrometry-based metabolomics', Food and Chemical Toxicology, 120, pp. 439-447. doi:10.1016/j.fct.2018.07.033 Preclinical
https://doi.org/10.1016/j.fct.2018.07.033 - Douglas, J.A., Follett, J.M., Parmenter, G.A., Sansom, C.E., Perry, N.B. and Littler, R.A (2010) 'Seasonal variation of biomass and bioactive alkaloid content of goldenseal, Hydrastis canadensis', Fitoterapia, 81(7), pp. 925-928. doi:10.1016/j.fitote.2010.06.006 Preclinical
https://doi.org/10.1016/j.fitote.2010.06.006 - Singh, S., Pathak, N., Fatima, E. and Negi, A.S (2021) 'Plant isoquinoline alkaloids: Advances in the chemistry and biology of berberine', European Journal of Medicinal Chemistry. doi:10.1016/j.ejmech.2021.113839 Preclinical
https://doi.org/10.1016/j.ejmech.2021.113839 - World Health Organization (2007) 'Rhizoma Hydrastis'. Available at: https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 Traditional / reference
https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 - Sevior, D.K., Hokkanen, J., Tolonen, A., Abass, K., Tursas, L., Pelkonen, O. and Ahokas, J.T (2010) 'Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail', Xenobiotica, 40(4), pp. 245--254. doi:10.3109/00498251003592683 Preclinical
https://doi.org/10.3109/00498251003592683 - Gurley, B.J., Gardner, S.F., Hubbard, M.A., Williams, D.K., Gentry, W.B., Khan, I.A. and Shah, A (2005) 'In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes', Clinical Pharmacology and Therapeutics, 77(5), pp. 415-426. doi:10.1016/j.clpt.2005.01.009 Randomized trial
https://doi.org/10.1016/j.clpt.2005.01.009 - McDonald, M.G., Tian, D.D., Thummel, K.E., Paine, M.F. and Rettie, A.E (2020) 'Modulation of major human liver microsomal cytochromes P450 by component alkaloids of goldenseal: time-dependent inhibition and allosteric effects', Drug Metabolism and Disposition, 48(10), pp. 1018-1027. doi:10.1124/dmd.120.091041 Preclinical
https://doi.org/10.1124/dmd.120.091041 - Guo, J., Chen, H., Zhang, X., Lou, W., Zhang, P., Qiu, Y., Zhang, C., Wang, Y. and Liu, W.J (2021) 'The effect of berberine on metabolic profiles in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials', Oxidative Medicine and Cellular Longevity, 2021, pp. 2074610. doi:10.1155/2021/2074610 Meta-analysis / review
https://doi.org/10.1155/2021/2074610 - Forest Farming (Cooperative Extension) 'Goldenseal (Hydrastis canadensis L.)'. Available at: https://forest-farming.extension.org/goldenseal-hydrastis-canadensis-l/ Traditional / reference
https://forest-farming.extension.org/goldenseal-hydrastis-canadensis-l/ - Frasca, T. and Brett, A.S. and Yoo, S.D (1997) 'Mandrake toxicity. A case of mistaken identity', Archives of Internal Medicine, 157(17), pp. 2007-9. doi:10.1001/archinte.157.17.2007 Clinical study
https://doi.org/10.1001/archinte.157.17.2007 - North Carolina Extension Gardener Plant Toolbox 'Sanguinaria canadensis (Bloodroot)'. Available at: https://plants.ces.ncsu.edu/plants/sanguinaria-canadensis/ Traditional / reference
https://plants.ces.ncsu.edu/plants/sanguinaria-canadensis/
- Ng, Q.X., Venkatanarayanan, N. and Ho, C.Y.X (2017) 'Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis', Journal of Affective Disorders, 210, pp. 211-221. doi:10.1016/j.jad.2016.12.048 Meta-analysis / review
https://doi.org/10.1016/j.jad.2016.12.048 - Kholghi, G., Arjmandi-Rad, S., Zarrindast, M.R. and Vaseghi, S (2022) 'St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?', Naunyn-Schmiedeberg's Archives of Pharmacology, 395(6), pp. 629-642. doi:10.1007/s00210-022-02229-z Traditional / reference
https://doi.org/10.1007/s00210-022-02229-z - Fugh-Berman, A (2000) 'Herb-drug interactions', Lancet, 355(9198), pp. 134-138. doi:10.1016/S0140-6736(99)06457-0 Traditional / reference
https://doi.org/10.1016/S0140-6736(99)06457-0 - Nobakht, S.Z., Akaberi, M., Mohammadpour, A.H., Tafazoli Moghadam, A. and Emami, S.A (2022) 'Hypericum perforatum: Traditional uses, clinical trials, and drug interactions', Iranian Journal of Basic Medical Sciences, 25(9), pp. 1045-1058. doi:10.22038/IJBMS.2022.65112.14338 Meta-analysis / review
https://doi.org/10.22038/IJBMS.2022.65112.14338 - Jiang, Z., Wang, F., Zhao, Y., Lu, L., Jiang, X., Huang, T., Lin, Y., Guo, L., Weng, Z. and Liu, E (2024) 'Hypericum perforatum L. attenuates depression by regulating Akkermansia muciniphila, tryptophan metabolism and NFkB-NLRP2-Caspase1-IL1beta pathway', Phytomedicine, 132, pp. 155847. doi:10.1016/j.phymed.2024.155847 Preclinical
https://doi.org/10.1016/j.phymed.2024.155847 - Oliveira, A.I., Pinho, C., Sarmento, B. and Dias, A.C.P (2016) 'Neuroprotective Activity of Hypericum perforatum and Its Major Components', Frontiers in Plant Science, 7, pp. 1004. doi:10.3389/fpls.2016.01004 Meta-analysis / review
https://doi.org/10.3389/fpls.2016.01004 - Russo, E., Scicchitano, F., Whalley, B.J., Mazzitello, C., Ciriaco, M., Esposito, S., Patane, M., Upton, R., Pugliese, M., Chimirri, S., Mammi, M., Palleria, C. and De Sarro, G (2013) 'Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions', Phytotherapy Research, 28(5), pp. 643-655. doi:10.1002/ptr.5050 Meta-analysis / review
https://doi.org/10.1002/ptr.5050 - Saddiqe, Z., Naeem, I. and Maimoona, A (2010) 'A review of the antibacterial activity of Hypericum perforatum L', Journal of Ethnopharmacology, 131(3), pp. 511-521. doi:10.1016/j.jep.2010.07.034 Meta-analysis / review
https://doi.org/10.1016/j.jep.2010.07.034 - Mennini, T. and Gobbi, M (2004) 'The antidepressant mechanism of Hypericum perforatum', Life Sciences, 75(9), pp. 1021-1027. doi:10.1016/j.lfs.2004.04.005 Meta-analysis / review
https://doi.org/10.1016/j.lfs.2004.04.005 - Liu, Y., Jiang, Y., Huang, R., Yang, J., Xiao, B. and Dong, J (2013) 'Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety', Climacteric, 17(4), pp. 325-335. doi:10.3109/13697137.2013.861814 Meta-analysis / review
https://doi.org/10.3109/13697137.2013.861814 - Wurglics, M. and Schubert-Zsilavecz, M (2006) 'Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients', Clinical Pharmacokinetics, 45(5), pp. 449-468. doi:10.2165/00003088-200645050-00002 Meta-analysis / review
https://doi.org/10.2165/00003088-200645050-00002 - Kasper, S (2001) 'Hypericum perforatum - a review of clinical studies', Pharmacopsychiatry, 34(Suppl 1), pp. S51-S55. doi:10.1055/s-2001-15467 Meta-analysis / review
https://doi.org/10.1055/s-2001-15467 - Nathan, P (1999) 'The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.)', Molecular Psychiatry, 4(4), pp. 333-338. doi:10.1038/sj.mp.4000557 Meta-analysis / review
https://doi.org/10.1038/sj.mp.4000557 - Verotta, L (2003) 'Hypericum perforatum, a source of neuroactive lead structures', Current Topics in Medicinal Chemistry, 3(2), pp. 187-201. doi:10.2174/1568026033392589 Meta-analysis / review
https://doi.org/10.2174/1568026033392589 - Linde, K. et al (2008) 'St John'. Traditional / reference
https://scholar.google.com/scholar?q=St%20John - Natural Standard (2013) 'Hypericum perforatum (St'. Traditional / reference
https://scholar.google.com/scholar?q=Hypericum%20perforatum%20%28St - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Zhou, S., Chan, E., Pan, S.Q., Huang, M. and Lee, E.J.D (2004) 'Pharmacokinetic interactions of drugs with St John's wort', Journal of Psychopharmacology, 18(2), pp. 262-276. doi:10.1177/0269881104042632 Meta-analysis / review
https://doi.org/10.1177/0269881104042632 - Izzo, A.A. and Ernst, E (2009) 'Interactions between herbal medicines and prescribed drugs: an updated systematic review', Drugs, 69(13), pp. 1777-1798. doi:10.2165/11317010-000000000-00000 Meta-analysis / review
https://doi.org/10.2165/11317010-000000000-00000 - Borrelli, F. and Izzo, A.A (2009) 'Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations', The AAPS Journal, 11(4), pp. 710-727. doi:10.1208/s12248-009-9146-8 Meta-analysis / review
https://doi.org/10.1208/s12248-009-9146-8 - Nicolussi, S., Drewe, J., Butterweck, V. and Meyer zu Schwabedissen, H.E (2020) 'Clinical relevance of St. John's wort drug interactions revisited', British Journal of Pharmacology, 177(6), pp. 1212-1226. doi:10.1111/bph.14936 Meta-analysis / review
https://doi.org/10.1111/bph.14936 - Piscitelli, S.C., Burstein, A.H., Chaitt, D., Alfaro, R.M. and Falloon, J (2000) 'Indinavir concentrations and St John's wort', Lancet, 355(9203), pp. 547-548. doi:10.1016/S0140-6736(99)05712-8 Clinical study
https://doi.org/10.1016/S0140-6736(99)05712-8 - Barone, G.W., Gurley, B.J., Ketel, B.L., Lightfoot, M.L. and Abul-Ezz, S.R (2000) 'Drug interaction between St. John's wort and cyclosporine', Annals of Pharmacotherapy, 34(9), pp. 1013-1016. doi:10.1345/aph.10088 Clinical study
https://doi.org/10.1345/aph.10088 - Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
https://doi.org/10.1016/j.contraception.2004.11.004 - Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
https://doi.org/10.1016/j.contraception.2004.11.004 - Pfrunder, A., Schiesser, M., Gerber, S., Haschke, M., Bitzer, J. and Drewe, J (2003) 'Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial', British Journal of Clinical Pharmacology, 56(6), pp. 683-690. doi:10.1046/j.1365-2125.2003.02005.x Randomized trial
https://doi.org/10.1046/j.1365-2125.2003.02005.x - Johne, A., Brockmoller, J., Bauer, S., Maurer, A., Langheinrich, M. and Roots, I (1999) 'Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)', Clinical Pharmacology and Therapeutics, 66(4), pp. 338-345. doi:10.1053/cp.1999.v66.a101944 Clinical study
https://doi.org/10.1053/cp.1999.v66.a101944 - Mathijssen, R.H.J., Verweij, J., de Bruijn, P., Loos, W.J. and Sparreboom, A (2002) 'Effects of St. John's wort on irinotecan metabolism', Journal of the National Cancer Institute, 94(16), pp. 1247-1249. doi:10.1093/jnci/94.16.1247 Randomized trial
https://doi.org/10.1093/jnci/94.16.1247 - Smith, P., Bullock, J.M., Booker, B.M., Haas, C.E., Berenson, C.S. and Jusko, W.J (2004) 'The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate', Pharmacotherapy, 24(11), pp. 1508-1514. doi:10.1592/phco.24.16.1508.50958 Clinical study
https://doi.org/10.1592/phco.24.16.1508.50958 - Izzo, A.A (2004) 'Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence', International Journal of Clinical Pharmacology and Therapeutics, 42(3), pp. 139-148. doi:10.5414/cpp42139 Meta-analysis / review
https://doi.org/10.5414/cpp42139 - Caus, M.N., Lupoae, M. and Chitescu, C.L (2026) 'Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks', Pharmaceuticals, 19(3), pp. 399. doi:10.3390/ph19030399 Meta-analysis / review
https://doi.org/10.3390/ph19030399
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.